Latest private-offering notice per company (SEC Form D), every US federal award on record, and financings published in the last 12 months.
CompanyOwnershipLatest private raise (sold)Notice filedNotices since 2019Federal obligationsFinancings (12m)Latest development
Precision Neuroscience
Neurotechnology & BCI
Privately held$250.0MSep 28, 20266—1Sep 28, 2026
Cambrian Bio
Longevity
Privately held$123.8MJul 15, 20266—1Jul 15, 2026
Lifeward
Physical augmentation
Publicly listed · Nasdaq: LFWD$11.2MJul 8, 202611$1.8M3Oct 27, 2026
Rejuvenate Bio
Longevity · Gene & cell engineering
Privately held$19.5MJun 18, 20262$5.1M1Jun 18, 2026
Life Biosciences
Longevity
Privately held$31.0MApr 24, 20265—1Apr 24, 2026
electroCore
Neurotechnology & BCI
Publicly listed · Nasdaq: ECOR$0Apr 15, 202614$390K1Sep 8, 2026
Longeveron
Longevity · Regeneration
Publicly listed · Nasdaq: LGVN$15.9MMar 25, 20269—1Oct 26, 2026
Science Corp.
Neurotechnology & BCI · Physical augmentation
Privately held$230.0MMar 6, 20264—1Mar 6, 2026
ClearPoint Neuro
Neurotechnology & BCI
Publicly listed · Nasdaq: CLPT$17.9MFeb 5, 20262$184K1Oct 28, 2026
Neuralink
Neurotechnology & BCI
Privately held$649.0MJun 12, 20255—0Jun 12, 2025
NewLimit
Longevity
Privately held$129.8MMay 15, 20253—0May 15, 2025
Loyal (Cellular Longevity)
Longevity
Privately held$22.2MOct 28, 20246—0—
BrainsWay
Neurotechnology & BCI
Publicly listed · Nasdaq: BWAY$20.0MOct 15, 20241—0Oct 26, 2026
NeuroOne Medical
Neurotechnology & BCI
Publicly listed · Nasdaq: NMTC$276KAug 16, 20249—0Oct 5, 2026
Colossal Biosciences
Synthetic biology
Privately held$162.6MJul 23, 20242—0—
BioAge Labs
Longevity
Publicly listed · Nasdaq: BIOA$194.4MFeb 13, 20241—0Aug 5, 2026
Paradromics
Neurotechnology & BCI
Privately held$50.1MNov 7, 20237$3.2M0—
Synchron
Neurotechnology & BCI
Privately held$49.9MDec 20, 20223—0—
Vivani Medical
Physical augmentation
Publicly listed · Nasdaq: VANI$27.9MApr 7, 20211—0Aug 13, 2026
NeuroPace
Neurotechnology & BCI
Publicly listed · Nasdaq: NPCE$69.4MAug 31, 20201$10.8M0Aug 11, 2026
Sana Biotechnology
Gene & cell engineering · Regeneration
Publicly listed · Nasdaq: SANA$45.9MJun 26, 20202—0Aug 10, 2026
CRISPR Therapeutics
Gene & cell engineering
Publicly listed · Nasdaq: CRSP$1.0MApr 10, 20202—0Oct 19, 2026
Beam Therapeutics
Gene & cell engineering
Publicly listed · Nasdaq: BEAM$83.6MMar 26, 20192—0Aug 4, 2026
Ginkgo Bioworks
Synthetic biology
Publicly listed · NYSE: DNA———$166.8M0Aug 5, 2026
Twist Bioscience
Synthetic biology
Publicly listed · Nasdaq: TWST———$6.7M1Aug 4, 2026
Myomo
Physical augmentation
Publicly listed · NYSE: MYO———$3.1M0Oct 5, 2026
Humacyte
Regeneration
Publicly listed · Nasdaq: HUMA———$1.6M1Sep 22, 2026
Neuronetics
Neurotechnology & BCI
Publicly listed · Nasdaq: STIM———$829K0Aug 11, 2026
Nexalin Technology
Neurotechnology & BCI
Publicly listed · Nasdaq: NXL————3Sep 28, 2026
Intellia Therapeutics
Gene & cell engineering
Publicly listed · Nasdaq: NTLA————1Sep 8, 2026
Dexcom
Biomonitoring
Publicly listed · Nasdaq: DXCM————0Sep 10, 2026
Lineage Cell Therapeutics
Regeneration
Publicly listed · NYSE: LCTX————0Aug 6, 2026
Prime Medicine
Gene & cell engineering
Publicly listed · Nasdaq: PRME————0Aug 6, 2026

How to read this

Latest private raise is the “total amount sold” in the company’s most recent Form D, the notice US companies file after selling securities without a public registration. It is cumulative for that offering and reported by the company. It is not a valuation, and the SEC does not review it.

Notices since 2019 counts Form D filings, including amendments that update an earlier notice. Never add the amounts together: an amendment repeats and updates the same offering.

Federal obligations are amounts US agencies have committed under contracts and research grants (USAspending.gov). They are not revenue and not a contract’s ceiling.

Financings counts published financing developments: public companies’ own SEC reports, plus private offering notices.

What this map is not

It is not a ranking of science, a valuation, an offer or investment advice. A past private raise does not mean shares are available to anyone now. Public companies’ market value is deliberately absent: we track what was filed, not prices.

Companies outside the US, or that never file a Form D, are missing here; absence is not evidence of no funding. Records can be revised; we keep the latest version and note changes.

Use it, cite it, link it. Please attribute “Sapien Frontier Funding Map” with a link to this page.

Full methodology